Nearmedic Plus LLC   Report issue

For profit Phase 2
Founded: Moscow Russian Federation (1989)

Organization Overview

First Clinical Trial
2016
NCT03036163
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Nearmedic Plus LLC

Active Ingredients

Drugs in Phase 2 Trials (2)

isoniazid (nydrazid) (1 trial)

pbtz169 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Tuberculosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2